Suzana Margareth Lobo, Gaétan Plantefève, Girish Nair, Adilson Joaquim Cavalcante, Nara Franzin de Moraes, Estevao Nunes, Otis Barnum, Claudio Marcel Berdun Stadnik, Maria Patelli Lima, Muriel Lins, Ludhmila Abrahao Hajjar, Christopher Lipinski, Shaheen Islam, Fabiano Ramos, Tiago Simon, Jean-Benoît Martinot, Thomas Guimard, Arnaud Desclaux, Bertrand Lioger, Fernando Carvalho Neuenschwander, Bruno DeSouza Paolino, Alpesh Amin, Samuel Amil Acosta, Daniel Forde Dilling, Edgardo Cartagena, Brian Snyder, Edouard Devaud, Ana Karolina Barreto Berselli Marinho, Suzana Tanni, Patricia Medeiros Milhomem Beato, Stephan De Wit, Vani Selvan, Jeffrey Gray, Ricardo Fernandez, Valérie Pourcher, Lee Maddox, Richard Kay, Anait Azbekyan, Mounia Chabane, Cendrine Tourette, Luis Everton Esmeraldino, Pierre J Dilda, René Lafont, Jean Mariani, Serge Camelo, Sandrine Rabut, Samuel Agus, Stanislas Veillet, Waly Dioh, Rob van Maanen, Capucine Morelot-Panzini
BACKGROUND: SARS-CoV-2 binding to ACE2 is potentially associated with severe pneumonia due to COVID-19. The aim of the study was to test whether Mas-receptor activation by 20-hydroxyecdysone (BIO101) could restore the Renin-Angiotensin System equilibrium and limit the frequency of respiratory failure and mortality in adults hospitalized with severe COVID-19. METHODS: Double-blind, randomized, placebo-controlled phase 2/3 trial. Randomization: 1:1 oral BIO101 (350 mg BID) or placebo, up to 28 days or until an endpoint was reached...
February 2024: EClinicalMedicine